| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Jun―30 |
Molecular pathways for targeted therapeutics in the management of COVID-19 and heart failure |
Paramvir Singh Tomar, Shikha Yadav, Sarad Pawar Naik Bukke, Ananda Kumar Chettupalli, Bayapa Reddy Narapureddy, Ayman Y. Waddad, et al. (+3) Ungo-Kore Hussain Yahaya, Chandrashekar Thalluri, Hope Onohuean |
| 2 |
[GO] |
2023―Nov―28 |
Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis |
Hu Luoyi, Pan Yan, Fan Qihong, Vijaya Anand |
| 3 |
[GO] |
2023―Apr―04 |
Single Nucleotide Variants (SNVs) of Angiotensin-Converting Enzymes (ACE1 and ACE2): A Plausible Explanation for the Global Variation in COVID-19 Prevalence |
Saad Mahjub Atiku, Dennis Kasozi, Katrina Campbell, Lawrence Aderemi Olatunji |
| 4 |
[GO] |
2023―Feb―27 |
Review on the Biogenesis of Platelets in Lungs and Its Alterations in SARS-CoV-2 Infection Patients |
Balasundaram Nandhini, Yacobu Sureshraj, Mohandass Kaviya, Thangavelu Sangeetha, Kathirvel Bharathi, Balasubramanian Balamuralikrishnan, et al. (+7) Pappuswamy Manikantan, Meyyazhagan Arun, Kuchi Bhotla Haripriya, Pushparaj Karthika, Subramaniam Kalidass, Arumugam Vijaya Anand, Lawrence Aderemi Olatunji |
| 5 |
[GO] |
2022―May―27 |
The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection |
Elisabeth Schieffer, Bernhard Schieffer, Xiaomu Li |
| 6 |
[GO] |
2022―Mar―18 |
Cardiorenal Disease in COVID-19 Patients |
Muhtasham Sifaat, Pinak Patel, Razan Sheikh, Dawood Ghaffar, Hitesh Vaishnav, Ludmila Nahar, et al. (+3) Sonia Rupani, Syed Quadri, Vijaya Anand |
| 7 |
[GO] |
2022―Feb―03 |
Ocular Distribution of the Renin-Angiotensin-Aldosterone System in the Context of the SARS-CoV-2 Pandemic |
Ali Abid, Muhammad Azaan Khan, Brendon Lee, Andrew White, Nicole Carnt, Sana Arshad, et al. (+2) Chameen Samarawickrama, Vijaya Anand |
| 8 |
[GO] |
2021―Nov―09 |
Alamandine: Potential Protective Effects in SARS-CoV-2 Patients |
Ava Soltani Hekmat, Kazem Javanmardi, Vijaya Anand |
| 9 |
[GO] |
2021―Sep―17 |
Human Ace D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19 |
Elifcan Aladag, Zahit Tas, Bilgesu Safak Ozdemir, Tayfun Hilmi Akbaba, Meltem Gulsun Akpınar, Hakan Goker, et al. (+8) Tugce Unalan-Altintop, Ahmet Cagkan Inkaya, Alpaslan Alp, Gokhan Metan, Ibrahim Celalettin Haznedaroglu, Banu Balci-Peynircioglu, Nilgun Sayinalp, Vijaya Anand |
| 10 |
[GO] |
2021―Jun―15 |
Effects of the Na+/H+ Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease |
Medine Cumhur Cure, Erkan Cure, Vijaya Anand |
| 11 |
[GO] |
2021―Jun―05 |
Exploring the Mystery of Angiotensin-Converting Enzyme II (ACE2) in the Battle against SARS-CoV-2 |
Divakar Sharma, Juhi Sharma, Amit Singh, Vijaya Anand |
| 12 |
[GO] |
2021―May―14 |
Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series |
Su Jin Lee, Taehwa Kim, Woo Hyun Cho, Doosoo Jeon, Seungjin Lim, Peter Sever |
| 13 |
[GO] |
2021―Jan―14 |
The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients |
Amer Harky, Cheryl Yan Ting Chor, Henry Nixon, Milad Jeilani |
| 14 |
[GO] |
2020―Dec―16 |
Effects of ACEI and ARB on COVID-19 patients: A meta-analysis |
Yang Xue, Shaoqing Sun, Jianing Cai, Linwen Zeng, Shihui Wang, Suhuai Wang, et al. (+3) Jingjie Li, Lin Sun, Jianmin Huo |
| 15 |
[GO] |
2020―Dec―10 |
Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads |
Martijn Hoevenaar, Dolf Goossens, Janne Roorda |
| 16 |
[GO] |
2020―Nov―12 |
COVID-19 and the pulmonary vascular injury |
Hai-Long Dai, Xue-Feng Guang |
| 17 |
[GO] |
2020―Nov―10 |
Angiotensin II, III, and IV may be important in the progression of COVID-19 |
Erkan Cure, Tevfik Bulent Ilcol, Medine Cumhur Cure |
| 18 |
[GO] |
2020―Nov―10 |
Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection |
Maira Soto, Gere diZerega, Kathleen E Rodgers |
| 19 |
[GO] |
2020―Nov―10 |
Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension |
Erkan Cure, Medine Cumhur Cure, Hulya Vatansev |
| 20 |
[GO] |
2020―Oct―10 |
Lifestyle and severe SARS-CoV-2 infections: Does the individual metabolic burden determines the outcome? |
Birgit Markus, Julian Kreutz, Bernhard Schieffer |
| 21 |
[GO] |
2020―Sep―15 |
Could angiotensin-converting enzyme 1 I/D polymorphism be a modificator of COVID-19 response in different populations, diseases, and/or conditions? |
Sanja Dević Pavlić, Sergej Nadalin, Nada Starčević Čizmarević, Alena Buretić-Tomljanović, Anđelka Radojčić Badovinac, Smiljana Ristić |
| 22 |
[GO] |
2020―Jun―03 |
In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus |
Can Turk, Seyhan Turk, Elif Sena Temirci, Umit Yavuz Malkan, İbrahim C. Haznedaroglu |
| 23 |
[GO] |
2020―May―21 |
Cardiovascular disease, heart failure and COVID-19 |
Luca Faconti, Philip J Chowienczyk, Ajay M Shah |
| 24 |
[GO] |
2020―May―20 |
COVID-19 and hypertension |
Spoorthy Kulkarni, Bernadette L. Jenner, Ian Wilkinson |
| 25 |
[GO] |
2020―May―15 |
Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression |
Raymond Pranata, Michael Anthonius Lim, Ian Huang, Sunu Budhi Raharjo, Antonia Anna Lukito |
| 26 |
[GO] |
2020―May―14 |
COVID-19: The race for a vaccine |
Emily Lockey |
| 27 |
[GO] |
2020―May―14 |
The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor? |
Peter Sever, Sebastian L Johnston |
